Nisin for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Nisin may be beneficial for
COVID-19 according to the studies below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed nisin in detail.
, The antimicrobial peptide nisin promotes host cell survival during SARS-CoV-2 infection, Virology Journal, doi:10.1186/s12985-025-02921-5
Abstract COVID-19 has been a major public health concern for the past five years. While remarkable work has been done to develop therapies, there is still a need for more treatments to fight this disease. Recently, it was suggested that nisin, an FDA-approved antimicrobial compound, may interfere with SARS-CoV-2 entry into host cells. Here, we show that nisin does not inhibit SARS-CoV-2 replication in vitro. Surprisingly, nisin treatment leads to reduced host-cell death during infection in a dose-dependent manner, suggesting that nisin may mitigate SARS-CoV-2-induced pathology.